


Waters

THE SCIENCE OF WHAT'S POSSIBLE.®

<sup>1</sup>Waters Corporation, Milford, MA; <sup>2</sup>Pfizer Bioprocess Research & Development, Pearl River, NY; <sup>3</sup>Pfizer Analytical Research & Development, Pearl River, NY; <sup>4</sup>Pfizer Analytical Research & Development, Andover, MA

## METHODS



**Columns**

The figure displays four SEC-LC/MS chromatograms stacked vertically, labeled on the left as "Low Loading", "Moderate Loading", "High Loading", and "Naked mAb". Above the chromatograms, a diagram shows five antibody molecules with their heavy chain variable regions (blue) and light chain variable regions (red) numbered 0, 2, 4, 6, and 8, representing different positional isomers. The x-axis for all chromatograms is "Time (min)" ranging from 14.00 to 16.00. The y-axis represents intensity. In the "Low Loading" trace (blue), peaks are labeled at retention times 14.07310, 14.07710, 14.08050, 14.07610, and 14.07440. In the "Moderate Loading" trace (red), peaks are labeled at 14.07210, 14.07380, 14.08050, 14.07610, and 14.07410. In the "High Loading" trace (green), peaks are labeled at 14.07310, 14.07560, 14.07600, and 14.07470. In the "Naked mAb" trace (purple), a single sharp peak is labeled at 14.07210. The diagram at the top shows the five isomers with their respective heavy chain (blue) and light chain (red) variable regions.

Drug loading distribution and DAR						
	Low		Mod		High	
	HIC	LC/MS	HIC	LC/MS	HIC	LC/MS
ADC 2	0.81	0.74	0.38	0.41	0.07	0.05
ADC 4	1.14	1.17	1.67	1.57	1.23	1.17
ADC 6	0.75	0.60	1.61	1.45	1.72	1.71
ADC 8	0.12	0.21	0.78	0.97	2.95	3.05
DAR	2.83	2.72	4.44	4.40	5.97	5.97

**RP-LC/MS**

**1 = Fc/2** **2 = L**

**3 = L\*** **4 = Fc/2\*\***

**5 = Fd** **6 = Fd\***

**7 = H\*\*\***

**Naked mAb**

Item name: 2014 ADC Cys Fabu 113  
Channel name: 1: TQF MS (500-5000) ES+ (TOC)  
Description: low fabu, 0.5 mg/ml, Injection volume: 200

**Cys-Low**

Item name: 2014 ADC Cys Fabu 116  
Channel name: 1: TQF MS (500-5000) ES+ (TOC)  
Description: mod fabu, 0.5 mg/ml, Injection volume: 200

**Cys-Mod**

Item name: 2014 ADC Cys Fabu 117  
Channel name: 1: TQF MS (500-5000) ES+ (TOC)  
Description: high fabu, 0.5 mg/ml, Injection volume: 200

**Cys-High**

*Fig. 5. Total ion chromatogram of reverse phase separated sub units. The subunit structures for peaks 1-7 were shown above. Cys-ADCs samples were treated by FabULOUS and then reduced by DTT.*

- Steric hindrance inhibits cleavage, resulting in 7=H\*\*\* (+3 drugs) peak.

Fig. 5. Total ion chromatogram of reverse phase separated subunits. The subunit structures for peaks 1-7 were shown above. Cys-ADCs samples were treated by Fab/ULOUS and then reduced by DTT.

- Steric hindrance inhibits cleavage, resulting in 7=H\*\*\* (+3 drugs) peak.

Figure 2 displays MS/MS spectra and protein structure models for three different DAR (Drug-Targeting Agent) constructs: DAR 4, DAR 6a, and DAR 6c. The figure is organized into three rows, each corresponding to one construct. Each row contains four panels: 1st Dimension, 2nd Dimension, Deconvoluted mass spectrum, and Isoform.

- DAR 4:**
  - 1st Dimension:** HPLC chromatogram showing a peak at approximately 6.5 minutes, labeled "Heart-cut".
  - 2nd Dimension:** MS/MS spectrum showing two major peaks labeled "peak 1" (m/z ~16) and "peak 2" (m/z ~17).
  - Deconvoluted mass spectrum:** Two spectra are shown. The left spectrum (peak 1) has a major peak at 23,575.0 Da. The right spectrum (peak 2) has major peaks at 101,727.0 Da (labeled G0F), 101,740.0 Da (labeled G1F), and 101,753.0 Da (labeled G2F).
  - Isoform:** A protein structure model of a Y-shaped antibody with two Fab arms, each containing a DAR 4 molecule (red dot) attached to the heavy chain.
- DAR 6a:**
  - 1st Dimension:** HPLC chromatogram showing a peak at approximately 6.5 minutes, labeled "Heart-cut".
  - 2nd Dimension:** MS/MS spectrum showing two major peaks labeled "peak 1" (m/z ~16) and "peak 2" (m/z ~17).
  - Deconvoluted mass spectrum:** Two spectra are shown. The left spectrum (peak 1) has a major peak at 23,575.0 Da. The right spectrum (peak 2) has major peaks at 102,484.0 Da (labeled G1F) and 102,497.0 Da (labeled G2F).
  - Isoform:** A protein structure model of a Y-shaped antibody with two Fab arms, each containing a DAR 6a molecule (red dot) attached to the heavy chain.
- DAR 6c:**
  - 1st Dimension:** HPLC chromatogram showing a peak at approximately 6.5 minutes, labeled "Heart-cut".
  - 2nd Dimension:** MS/MS spectrum showing three major peaks labeled "peak 1" (m/z ~16), "peak 2" (m/z ~17), and "peak 3" (m/z ~18).
  - Deconvoluted mass spectrum:** Three spectra are shown. The left spectrum (peak 1) has a major peak at 23,575.0 Da. The middle spectrum (peak 2) has major peaks at 74,439.0 Da (labeled G0F) and 74,452.0 Da (labeled G1F). The right spectrum (peak 3) has major peaks at 51,620.0 Da (labeled G0F) and 51,633.0 Da (labeled G1F).
  - Isoform:** A protein structure model of a Y-shaped antibody with two Fab arms, each containing a DAR 6c molecule (red dot) attached to the heavy chain.

**LC/MS<sup>E</sup>**

1 2 3 4

Time

1 THTCPPCPAPEAAGAPSVLFPKKK  
2 THTCPPCPAPEAAGAPSVLFPKKK C: Carbamidomethyl Cys  
3 THTCPPCPAPEAAGAPSVLFPKKK C: Drug conjugated Cys  
4 THTCPPCPAPEAAGAPSVLFPKKK

Fig. 6. Tryptic peptide mapping MS<sup>E</sup> chromatogram of cys-conjugated ADC (Moderate). Heavy chain T21 peptides with two conjugation sites are shown as an example. Unconjugated T21 (1), T21 with 1 conjugation site (2 and 3), and T21 with 2 conjugation sites (4) are indicated on the chromatogram.

Chain	Pep#	Peptide sequence	Modifier	Drug Occupancy ratio
Light	1:T2	VTITCR	ADC_cys	7.3%
Light	1:T11	SGTASVYVCLNNFYPR	ADC_cys	1.2%
Light	1:T18	VYACEVTHQGLSSPVTK	ADC_cys	2.1%
Light	1:T20	GECC	ADC_cys	100.0%
Heavy	2:T11	AEDTAVVYCAR	ADC_cys	1.9%
Heavy	2:T15	STSGGTAALGCLVK	ADC_cys	1.9%
Heavy	2:T20	SCDK	ADC_cys	100.0%
Heavy	2:T21	THTCPPCPAPEAAGAPSVLFPPKPK	ADC_cys, CAM	5.9%
Heavy	2:T21	THTCPPCPAPEAAGAPSVLFPPKPK	ADC_cys, CAM	4.8%
Heavy	2:T21	THTCPPCPAPEAAGAPSVLFPPKPK	ADC_cys x2	24.6%
Heavy	2:T23	TPETVCPVVVDVSHEDPEVK	ADC_cys	1.5%
Heavy	2:T37	NQVSLTCLVK	ADC_cys	3.5%
Heavy	2:T42	WQQGNVFSCVSMHEALHNHYTQK	ADC_cys	1.4%

Table 2. List of cys-conjugated peptides observed in the moderate loading sample. Drug occupancy ratio = MS intensity of conjugated/(MS intensity of unconjugated +conjugated peptides)

- DAR values and drug loading distributions for cysteine-conjugated ADCs are automatically acquired from HIC-LC analysis and from native SEC-LC/MS analysis, and the results show excellent agreement.
- 2D-LC/MS provides unambiguous identification of positional isomers in cysteine-conjugated ADCs.
- LC/MS<sup>E</sup> identifies 13 conjugation sites with drug occupancy ratio calculated.

**TO DOWNLOAD A COPY OF THIS POSTER, VISIT [WWW.WATERS.COM/POSTERS](http://WWW.WATERS.COM/POSTERS)**